Cue Health submitted its Covid-19 test to the FDA for Emergency Use Authorization. The company is developing a portable testing platform that sends results to users’ smartphones. Photo credit: Cue Health
Cue Health, a startup developing a connected testing device, raised $100 million in funding. The San Diego-based company plans to use the funds to validate its testing platform and scale up its manufacturing facility.
Changes in Nurse Staffing Answer Clinician Demands
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.
The system uses disposable cartridges specific to each disease. It then sends the results to the patient’s smartphone, which they could pull up in a telemedicine consult. Cue Health currently has a 55,0000-square-foot manufacturing site in San Diego and plans to scale its facility up to more than 110,000 square feet.
Cue Health also plans to put the funds toward seeking FDA clearance for its first product, an at-home test for influenza A and B. The company is currently in validation trials that it will use for its FDA 510(k) submission. In 2018, the startup received a $30 million grant from the Biomedical Advanced Research and Development Authority (BARDA) to develop an over-the-counter flu test.
Cue Health also developed a rapid, molecular Covid-19 test that it submitted to the FDA for emergency use authorization. The test would use a nasal swab, and would be able to produce results in less than half an hour. BARDA also funded this effort, awarding a $13 million contract to Cue in March.
“The Covid-19 pandemic has highlighted the need for a rapid, easy-to-use platform for diagnostics in decentralized settings to respond to existing and emerging threats,” Cue CEO and Co-Founder Ayub Khattak said in a news release. “Healthcare settings such as nursing homes, emergency departments, and community health clinics need tools to allow them to access molecular test information immediately rather than waiting hours or days for lab results.”
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
Menlo Park-based Decheng Capital, Foresite Capital, Madrone Capital Partners, Johnson & Johnson Innovation and ACME Capital participated in Cue’s series C round. The company previously raised $45 million in 2018.
Photo credit: Abscent84, Getty Images